[go: up one dir, main page]

WO2007031329A3 - Utilisation de collagene d'origine xenogene - Google Patents

Utilisation de collagene d'origine xenogene Download PDF

Info

Publication number
WO2007031329A3
WO2007031329A3 PCT/EP2006/009004 EP2006009004W WO2007031329A3 WO 2007031329 A3 WO2007031329 A3 WO 2007031329A3 EP 2006009004 W EP2006009004 W EP 2006009004W WO 2007031329 A3 WO2007031329 A3 WO 2007031329A3
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
xenogeneic origin
xenogeneic
origin
constrictions
Prior art date
Application number
PCT/EP2006/009004
Other languages
German (de)
English (en)
Other versions
WO2007031329A2 (fr
Inventor
Arne Briest
Marco Springer
Original Assignee
Ossacur Ag
Arne Briest
Marco Springer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ossacur Ag, Arne Briest, Marco Springer filed Critical Ossacur Ag
Publication of WO2007031329A2 publication Critical patent/WO2007031329A2/fr
Publication of WO2007031329A3 publication Critical patent/WO2007031329A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation de collagène d'origine xénogène pour induire et/ou renforcer une néovascularisation, ainsi que pour empêcher et/ou traiter des maladies liées à des anomalies vasculaires se présentant en particulier sous la forme de rétrécissements et/ou d'occlusions. Selon l'invention, ledit collagène comporte un complexe actif.
PCT/EP2006/009004 2005-09-15 2006-09-15 Utilisation de collagene d'origine xenogene WO2007031329A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005045671.5 2005-09-15
DE102005045671A DE102005045671A1 (de) 2005-09-15 2005-09-15 Verwendung eines Kollagens xenogenen Ursprungs

Publications (2)

Publication Number Publication Date
WO2007031329A2 WO2007031329A2 (fr) 2007-03-22
WO2007031329A3 true WO2007031329A3 (fr) 2007-07-12

Family

ID=37564137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009004 WO2007031329A2 (fr) 2005-09-15 2006-09-15 Utilisation de collagene d'origine xenogene

Country Status (2)

Country Link
DE (1) DE102005045671A1 (fr)
WO (1) WO2007031329A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093880A1 (fr) * 2000-06-05 2001-12-13 Yale University Production et utilisation de microvaisseaux dans un gel contenant de la fibronectine
WO2002022157A2 (fr) * 2000-09-14 2002-03-21 Transkaryotic Therapies, Inc. Melanges de matrices hydrides pouvant etre injectes
US20050064521A1 (en) * 2003-09-24 2005-03-24 Tunghai University In vitro assay for evaluation of angiogenic effects

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US6419920B1 (en) * 1995-10-25 2002-07-16 Trans Karyotic Therapies, Inc. Hybrid matrix implants and explants
US5962025A (en) * 1996-07-16 1999-10-05 The University Of Tennessee Research Corporation Method for treatment of systemic sclerosis and related fibrotic diseases
AU6654598A (en) * 1997-02-13 1998-09-08 Benedict, James A. Implantable collagen-containing putty material
US6328765B1 (en) * 1998-12-03 2001-12-11 Gore Enterprise Holdings, Inc. Methods and articles for regenerating living tissue
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
US20030007954A1 (en) * 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
WO2000064954A1 (fr) * 1999-04-22 2000-11-02 Vanderbilt University Systeme d'encapsulation de polymeres facilitant l'angiogenese
US6506398B1 (en) * 2000-04-28 2003-01-14 Hosheng Tu Device for treating diabetes and methods thereof
AU2002329884A1 (en) * 2001-08-27 2003-03-10 Regeneration Technologies, Inc. Processed soft tissue for topical or internal application
TWI245634B (en) * 2001-12-28 2005-12-21 Ind Tech Res Inst Preparation of a biodegradable thermal-sensitive gel system
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093880A1 (fr) * 2000-06-05 2001-12-13 Yale University Production et utilisation de microvaisseaux dans un gel contenant de la fibronectine
WO2002022157A2 (fr) * 2000-09-14 2002-03-21 Transkaryotic Therapies, Inc. Melanges de matrices hydrides pouvant etre injectes
US20050064521A1 (en) * 2003-09-24 2005-03-24 Tunghai University In vitro assay for evaluation of angiogenic effects

Also Published As

Publication number Publication date
WO2007031329A2 (fr) 2007-03-22
DE102005045671A1 (de) 2007-03-29

Similar Documents

Publication Publication Date Title
WO2008115469A3 (fr) Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
WO2007037849A3 (fr) Compositions et methodes pour le transport intraoculaire d'agents therapeutiques
WO2006091459A3 (fr) Compositions et methodes permettant de traiter la permeabilite vasculaire
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
TW200637522A (en) Skin treatment articles and methods
WO2007027761A3 (fr) Utilisation d'antagonistes de l'il-23 et de l'il-17 pour le traitement de la maladie inflammatoire oculaire auto-immune
WO2009091994A3 (fr) Fabrication d'enzymes de sulfatase lysosomales humaines hautement phosphorylées actives et leurs utilisations
WO2008029276A8 (fr) Compositions et procédés de traitement d'une maladie ophtalmique
WO2011065982A3 (fr) Polymorphismes associés à la maladie de parkinson
WO2006096434A3 (fr) Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2006013441A3 (fr) Utilisation de bacteries probiotiques dans la preparation de compositions topiques destinees a la protection de la peau
WO2008034013A3 (fr) Dispositifs médicaux et procédés de réalisation desdits dispositifs
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2010141648A3 (fr) Larmes artificielles et utilisations thérapeutiques
WO2007146965A3 (fr) Composés destinés au traitement d'une maladie périodontale
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
MY172372A (en) Compositions and methods for lowering triglycerides
WO2006116221A3 (fr) Nouvelles combinaisons therapeutiques pour le traitement ou la prevention de troubles psychotiques
WO2008060362A3 (fr) Procédés et compositions pour le traitement de maladies et de troubles de la peau
WO2007051785A3 (fr) Utilisation de sdf-1 pour le traitement et/ou la prevention de maladies neurologiques
WO2006079068A3 (fr) Compositions et methodes permettant d'etudier et de traiter des maladies et des troubles inflammatoires
WO2009103959A3 (fr) Médicament
WO2007012748A3 (fr) Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06792086

Country of ref document: EP

Kind code of ref document: A2